國家衛生研究院 NHRI:Item 3990099045/5229

NHRI > National Institute of Environmental Health Sciences > Huei Lee(2009-2011) > Periodical Articles > Item 3990099045/5229

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/5229

Title:	cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-Kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer
Authors:	Wu, HH;Wu, JY;Cheng, YW;Chen, CY;Lee, MC;Goan, YG;Lee, H
Contributors:	Division of Environmental Health and Occupational Medicine
Abstract:	PURPOSE: Inhibitors of antiapoptosis protein (IAP) have been implicated in the resistance to cisplatin. Therefore, verifying which pathway is involved in cIAP2 upregulation may be helpful in finding a feasible pathway inhibitor to increase the chemotherapeutic efficacy in human papillomavirus (HPV)-infected lung cancer. EXPERIMENTAL DESIGN: Specific inhibitors of different pathways were used to verify which pathway is involved in cIAP2 transcription. cIAP2 promoter fragments with various deletions and/or mutations were constructed by site-directed mutagenesis. cIAP2, epidermal growth factor receptor (EGFR), and phospho-AKT (p-AKT) expressions in 136 lung tumors were evaluated by immunohistochemistry. RESULTS: Our data show that two NF-kappaB (-209 to -200 and -146 to -137) and one CREB (cyclic AMP-responsive element binding protein; -52 to -42) binding sites in cIAP2 promoter region were responsible for cIAP2 upregulated by E6 in TL-1 cells. Moreover, CREB was phosphorylated by EGFR/phosphatidylinositol 3-kinase (PI3K) pathway. To test the involvement of cIAP2 on cisplatin resistance, IC(50) was lowered to 8.6 mumol/L in TL-1 cells with cIAP2 short hairpin RNA (shRNA) transfection and compared with 39.7 mumol/L in TL-1 cells with nonspecific shRNA. Pretreatment with EGFR or PI3K inhibitor in TL-1 cells diminished the resistance to cisplatin. Among the tumor groups, cIAP2 expression correlated significantly with HPV16/18 E6, EGFR, and p-AKT. We followed up 46 of 136 patients who had tumor recurrence and/or metastasis and underwent chemotherapy. Tumors with cIAP2-positive immunostaining were associated with a poorer tumor response to chemotherapy compared with those with negative immunostaining. CONCLUSIONS: cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer. Clin Cancer Res; 16(21); 5200-10.
Date:	2010-11
Relation:	Clinical Cancer Research. 2010 Nov;16(21):5200-5210.
Link to:	http://dx.doi.org/10.1158/1078-0432.ccr-10-0020
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1078-0432&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000283668500012
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=78049470974
Appears in Collections:	[Huei Lee(2009-2011)] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB20959404.pdf		384Kb	Adobe PDF	739	View/Open

Loading...